Ideas

Probiotic-based therapy for lowering cholesterol, and triglycerides levels:  Lactobacillus Paracasei OFS 0291(LP-0291) decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via up-regulation of its target gene, 22/January/2018, 10.19 pm
Probiotic-based therapy for lowering cholesterol, and triglycerides levels:  Lactobacillus Paracasei OFS 0291(LP-0291) decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via up-regulation of its target gene, 22/January/2018, 10.19 pm 960 720 Dr Boomi's Genom-2-Discovery Center

The significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people…

read more

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Mevastatin, an antipsychotic drug, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1,PDCD4,  p53, p21, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 19/January/2018, 5.33 pm
Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Mevastatin, an antipsychotic drug, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1,PDCD4,  p53, p21, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 19/January/2018, 5.33 pm 960 720 Dr Boomi's Genom-2-Discovery Center

What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that: Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in…

read more

Probiotic-based therapy for lowering cholesterol, and triglycerides levels: Bifidobacterium lactis HY8101 decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via up-regulation of its target gene, 18/December/2018, 12.10 am
Probiotic-based therapy for lowering cholesterol, and triglycerides levels: Bifidobacterium lactis HY8101 decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via up-regulation of its target gene, 18/December/2018, 12.10 am 960 720 Dr Boomi's Genom-2-Discovery Center

The significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people…

read more

RNA-based therapy for aging-associated diseases and Lifespan extension: LncRNA UCA1  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging, via down-regulation of its target gene, 18/January/2019, 12.04 am
RNA-based therapy for aging-associated diseases and Lifespan extension: LncRNA UCA1  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging, via down-regulation of its target gene, 18/January/2019, 12.04 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA, USA; and Department of Pharmacology, School…

read more

Probiotic-based therapy for lowering cholesterol, and triglycerides levels: Lactobacillus fermentum DR9 (LF-DR9) decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via up-regulation of its target gene, 17/December/2018, 11.55 pm
Probiotic-based therapy for lowering cholesterol, and triglycerides levels: Lactobacillus fermentum DR9 (LF-DR9) decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via up-regulation of its target gene, 17/December/2018, 11.55 pm 960 720 Dr Boomi's Genom-2-Discovery Center

The significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people…

read more

RNA-based therapy for aging-associated diseases and Lifespan extension: LncRNA MALAT/NEAT2  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging, via down-regulation of its target gene, 17/January/2019, 11.48 pm
RNA-based therapy for aging-associated diseases and Lifespan extension: LncRNA MALAT/NEAT2  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging, via down-regulation of its target gene, 17/January/2019, 11.48 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA, USA; and Department of Pharmacology, School…

read more
Start Typing